UNICYCIVE THERAPEUTICS INC (UNCY) — insider trading
Health Care · NASDAQ
UNICYCIVE THERAPEUTICS INC (UNCY) has 18 reported SEC Form 4 insider transactions in our data (latest 2026-05-14).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-05-14 | Laumas Sandeep | Director | Grant / award / vesting (derivative) | 47,941 | — | $0 | Form 4/A |
| 2026-05-14 | Kenkare-Mitra Sara | Director | Grant / award / vesting (derivative) | 47,941 | — | $0 | Form 4/A |
| 2026-05-14 | Jermasek Douglas | Officer (EVP, Corporate Strategy) | Grant / award / vesting (derivative) | 169,500 | — | $0 | Form 4/A |
| 2026-05-14 | Townsend John | Officer (CFO) | Grant / award / vesting (derivative) | 169,500 | — | $0 | Form 4/A |
| 2026-05-14 | Gupta Pramod | Officer (EVP, Pharmaceuticals and BD) | Grant / award / vesting (derivative) | 169,500 | — | $0 | Form 4/A |
| 2026-05-14 | Laumas Sandeep | Director | Grant / award / vesting (derivative) | 42,100 | — | $0 | Form 4/A |
| 2026-05-14 | Laumas Sandeep | Director | Grant / award / vesting (derivative) | 84,200 | — | $0 | Form 4/A |
| 2026-05-14 | Kenkare-Mitra Sara | Director | Grant / award / vesting (derivative) | 42,100 | — | $0 | Form 4/A |
| 2026-05-14 | Kenkare-Mitra Sara | Director | Grant / award / vesting (derivative) | 84,200 | — | $0 | Form 4/A |
| 2026-05-14 | Gupta Shalabh K. | Director, Officer (CEO) | Grant / award / vesting (derivative) | 762,200 | — | $0 | Form 4/A |
| 2026-05-14 | Kenkare-Mitra Sara | Director | Grant / award / vesting (derivative) | 42,100 | — | $0 | Form 4 |
| 2026-05-14 | Kenkare-Mitra Sara | Director | Grant / award / vesting (derivative) | 84,200 | — | $0 | Form 4 |
| 2026-05-14 | Gupta Shalabh K. | Director, Officer (CEO) | Grant / award / vesting (derivative) | 762,200 | — | $0 | Form 4 |
| 2026-05-14 | Townsend John | Officer (CFO) | Grant / award / vesting (derivative) | 169,500 | — | $0 | Form 4 |
| 2026-05-14 | Gupta Pramod | Officer (EVP, Pharmaceuticals and BD) | Grant / award / vesting (derivative) | 169,500 | — | $0 | Form 4 |
| 2026-05-14 | Jermasek Douglas | Officer (EVP, Corporate Strategy) | Grant / award / vesting (derivative) | 169,500 | — | $0 | Form 4 |
| 2026-05-14 | Laumas Sandeep | Director | Grant / award / vesting (derivative) | 42,100 | — | $0 | Form 4 |
| 2026-05-14 | Laumas Sandeep | Director | Grant / award / vesting (derivative) | 84,200 | — | $0 | Form 4 |
Ask the chat about UNCY's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: UNICYCIVE THERAPEUTICS INC (UNCY).
Last updated 2026-05-14 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.